- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Panel Discusses Costly New Oncology Drugs; Study Address Cancer Drug Shortages
Although researchers have made powerful new targeted treatment options available to oncologists who treat breast cancer patients, options such as pertuzumab are associated with high costs which raises questions about access as payers assess the value of treatment.
Although researchers have made powerful new targeted treatment options available to oncologists who treat breast cancer patients, options such as pertuzumab are associated with high costs which raises questions about access as payers assess the value of treatment. Pertuzumab, also known as Genentech’s Perjeta, is a recombinant humanized monoclonal antibody that is approved for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.
According to the American Journal of Managed Care, in one clinical trial, women treated with combination therapy with pertuzumab experienced significant improvements in progression-free survival, or six months greater on average, compared to women who received combination treatment with a placebo. These and other key issues surrounding proper utilization and reimbursement were the focus of an expert panel discussion that the American Journal of Managed Care convened.
Read the full story here: http://bit.ly/16bHQL5
Source: PharmaLive
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
